EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas.
Nat Med. 2017.
PMID: 28263309
Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
2 results
Citations
1
article
found by citation matching
Search results
Filters applied: . Clear all
Page 1
EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas.
Mohammad F, Weissmann S, Leblanc B, Pandey DP, Højfeldt JW, Comet I, Zheng C, Johansen JV, Rapin N, Porse BT, Tvardovskiy A, Jensen ON, Olaciregui NG, Lavarino C, Suñol M, de Torres C, Mora J, Carcaboso AM, Helin K.
Mohammad F, et al.
Nat Med. 2017 Apr;23(4):483-492. doi: 10.1038/nm.4293. Epub 2017 Feb 27.
Nat Med. 2017.
PMID: 28263309
Diffuse intrinsic pontine glioma (DIPG) is an aggressive brain tumor that is located in the pons and primarily affects children. ...Taken together, these results show that residual PRC2 activity is required for the proliferation of H3K27M-expressing DIPGs, and that inhibit …
Diffuse intrinsic pontine glioma (DIPG) is an aggressive brain tumor that is located in the pons and primarily affects children. ...T …
Item in Clipboard
Combination of EZH2 inhibitor and BET inhibitor for treatment of diffuse intrinsic pontine glioma.
Zhang Y, Dong W, Zhu J, Wang L, Wu X, Shan H.
Zhang Y, et al.
Cell Biosci. 2017 Oct 30;7:56. doi: 10.1186/s13578-017-0184-0. eCollection 2017.
Cell Biosci. 2017.
PMID: 29118968
Free PMC article.
More and more studies are focused on the genetic and epigenetic drivers of DIPGs, which may provide more and more novel therapy target for DIPG. EZH2 has been proved to be a potential therapeutic target for H3K27M-mutant pediatr …
More and more studies are focused on the genetic and epigenetic drivers of DIPGs, which may provide more and more novel therapy target …
Item in Clipboard
Cite
Cite